Login to Your Account

Myriad, Abbott Team In Deal To Diagnose, Treat Depression

By Kim Coghill

Wednesday, March 13, 2002
Myriad Genetics Inc. entered a deal worth upward of $34 million with Abbott Laboratories Inc. to identify genes and drug targets for the diagnosis and treatment of depression. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription